Joyson Poulose, MD
Guthrie Provider
- Hematology
- Medical Oncology
- Guthrie Robert Packer Hospital
Appointments & Contact
Accepting New Patients
Offers Telemedicine Visits
Information Icon
Telemedicine video visits make it easier to find care at a time and location that is convenient for you. Telemedicine appointments are available for both new patient visits and follow-ups.
For New Patients
Clinical Interests
- Bladder Cancer
- Head & Neck Cancer
- Lung Cancer
- Melanoma
- Prostate Cancer
- Renal Cell Cancer
- Testicular Cancer
Locations
- Also Offers Telemedicine Information Icon866-488-4743Telemedicine video visits make it easier to find care at a time and location that is convenient for you. Telemedicine appointments are available for both new patient visits and follow-ups.
Education
- Saint James School of Medicine, Bonaire, Netherlands-Antilles
- UPMC Pinnacle, Harrisburg, Pa. (Internal Medicine)
- Pennsylvania State University Milton S. Hershey Medical Center, Hershey, Pa. (Hematology/Oncology)
- American Board of Internal Medicine
- American Society of Clinical Oncology
- American Society of Hematology
News & Video
Clinical Trials
- A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T
- A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
- Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
- CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or
- EA1183: FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE
- EA5181: Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
- EA6141, Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
- FRNM-008 The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
- LungMap (Screening Protocol for Lung-Map):
- NRG-BR007: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
- NRG-LU007: Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
- OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
- Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study
- S1501, Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
- S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
- The Efficacy of Steroid-Sparing Anti-Emetic Therapy in Patients Treated with High Emetogenic Chemotherapy; Single Center Non-Inferiority Open Label Randomized Controlled Trial
Patient Comments